Jazz Pharmaceuticals PLC $JAZZ Stock Holdings Lowered by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP reduced its holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 27.8% during the first quarter, Holdings Channel reports. The firm owned 1,895,215 shares of the specialty pharmaceutical company’s stock after selling 728,088 shares during the period. Dimensional Fund Advisors LP’s holdings in Jazz Pharmaceuticals were worth $358,264,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in JAZZ. Vestal Point Capital LP bought a new stake in Jazz Pharmaceuticals during the second quarter worth approximately $127,344,000. Franklin Resources Inc. increased its holdings in shares of Jazz Pharmaceuticals by 164.0% in the fourth quarter. Franklin Resources Inc. now owns 1,818,911 shares of the specialty pharmaceutical company’s stock valued at $309,215,000 after buying an additional 1,129,995 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Jazz Pharmaceuticals by 160.2% during the 4th quarter. Bank of New York Mellon Corp now owns 1,161,857 shares of the specialty pharmaceutical company’s stock valued at $197,516,000 after acquiring an additional 715,361 shares during the last quarter. Adage Capital Partners GP L.L.C. lifted its position in shares of Jazz Pharmaceuticals by 258.2% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 548,000 shares of the specialty pharmaceutical company’s stock valued at $93,160,000 after acquiring an additional 395,000 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC lifted its position in shares of Jazz Pharmaceuticals by 592.1% during the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 436,443 shares of the specialty pharmaceutical company’s stock valued at $57,523,000 after acquiring an additional 373,383 shares during the last quarter. 89.14% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, Director Rick E. Winningham sold 2,741 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $241.57, for a total transaction of $662,143.37. Following the transaction, the director owned 9,567 shares of the company’s stock, valued at $2,311,100.19. The trade was a 22.27% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Neena M. Patil sold 1,200 shares of the company’s stock in a transaction dated Wednesday, June 10th. The shares were sold at an average price of $231.83, for a total value of $278,196.00. Following the completion of the transaction, the executive vice president owned 51,549 shares in the company, valued at $11,950,604.67. This represents a 2.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 13,098 shares of company stock worth $3,131,906. 4.10% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. TD Cowen lifted their target price on Jazz Pharmaceuticals from $220.00 to $275.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. UBS Group upgraded Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their price target for the company from $188.00 to $307.00 in a research report on Tuesday, May 19th. Deutsche Bank Aktiengesellschaft lifted their price target on Jazz Pharmaceuticals from $250.00 to $270.00 and gave the stock a “buy” rating in a research note on Thursday, July 9th. Morgan Stanley restated an “overweight” rating and set a $245.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, May 7th. Finally, Piper Sandler upped their price objective on shares of Jazz Pharmaceuticals from $232.00 to $301.00 and gave the company an “overweight” rating in a research note on Friday, May 22nd. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, Jazz Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $259.06.

Jazz Pharmaceuticals Price Performance

JAZZ opened at $254.22 on Wednesday. The stock has a fifty day moving average of $236.03 and a 200-day moving average of $201.74. The firm has a market capitalization of $15.97 billion, a P/E ratio of -12,704.65, a PEG ratio of 0.21 and a beta of 0.32. Jazz Pharmaceuticals PLC has a 12-month low of $105.00 and a 12-month high of $255.20. The company has a quick ratio of 1.85, a current ratio of 2.04 and a debt-to-equity ratio of 0.95.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share for the quarter. Jazz Pharmaceuticals had a return on equity of 14.56% and a net margin of 0.66%.The business had revenue of $1.07 billion for the quarter. Equities analysts forecast that Jazz Pharmaceuticals PLC will post 21.9 EPS for the current fiscal year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.